Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | F13A1 | P00488 | 2/20 | 0.36 |
| ▸ | TGM2 | P21980 | 2/20 | 0.36 |
| ▸ | TGM1 | P22735 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3316800 | 0.77 | CYP2C9 (0.50) | ALDH1A1POLBPKMGAAKDM4E | |
| SCHEMBL3317094 | 0.72 | PKM (0.57) | TDP1ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL5915288 | 0.72 | L3MBTL1 (0.54) | USP2ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL6809391 | 0.72 | ALDH1A1 (0.64) | USP2ALDH1A1KMT2AHTTMAPT | |
| SCHEMBL293776 | 0.72 | ALDH1A1 (0.51) | USP2ALDH1A1POLBPKMGAA | |
| SCHEMBL29687970 | 0.70 | POLB (0.67) | USP2ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL4575845 | 0.70 | ATM (0.63) | TDP1USP2MEN1KMT2APOLB | |
| Hydrochloric Acid SCHEMBL5733527 | 0.69 | MAPT (0.61) | TDP1USP2ALDH1A1F13A1TGM2 | |
| Lithium Ion SCHEMBL813502 | 0.68 | TDP1 (0.61) | TDP1HCRTR1HCRTR2ALDH1A1HTT | |
| SCHEMBL19915134 | 0.68 | TDP1 (0.61) | TDP1HCRTR1HCRTR2ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040132809-A1 | Cell adhesion inhibitors | BIOGEN, INC. | 2004-07-08 | — | — | US | claimed |
| US-6630503-B1 | Non-peptidic sulfonamide compounds that specifically inhibit the binding of ligands to VLA-4 for inhibition, prevention and suppression of VLA-4-mediated cell adhesion and pathologies such as inflammation and immune reactions | BIOGEN, INC. | 2003-10-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132809-A1 | Cell adhesion inhibitors | VCAM1, ICAM1, EPCAM | TDP1 3720/4885HCRTR1 3424/4885HCRTR2 4016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.